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Abstract
Background: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against
hepatocellular carcinoma (HCC) in vitro and palliative efficacy in advanced HCC in two independent phase II trials.
The aim of this study was to assess the efficacy of thymostimulin in a phase III trial.
Methods: The study was designed as a prospective randomised, placebo-controlled, double-blind, multicenter
clinical phase III trial. Between 10/2002 and 03/2005, 135 patients with locally advanced or metastasised HCC
(Karnofsky ≥60%/Child-Pugh ≤ 12) were randomised to receive thymostimulin 75 mg s.c. 5×/week or placebo
stratified according to liver function. Primary endpoint was twelve-month survival, secondary endpoints overall
survival (OS), time to progression (TTP), tumor response, safety and quality of life. A subgroup analysis according to
liver function, KPS and tumor stage (Okuda, CLIP and BCLC) formed part of the protocol.
Results: Twelve-month survival was 28% [95%CI 17-41; treatment] and 32% [95%CI 19-44; control] with no
significant differences in median OS (5.0 [95% CI 3.7-6.3] vs. 5.2 [95% CI 3.5-6.9] months; p = 0.87, HR = 1.04 [95%
CI 0.7-1.6]) or TTP (5.3 [95%CI 2.0-8.6] vs. 2.9 [95%CI 2.6-3.1] months; p = 0.60, HR = 1.13 [95% CI 0.7-1.8]).
Adjustment for liver function, Karnofsky status or tumor stage did not affect results. While quality of life was similar
in both groups, fewer patients on thymostimulin suffered from accumulating ascites and renal failure.
Conclusions: In our phase III trial, we found no evidence of any benefit to thymostimulin in the treatment of
advanced HCC and there is therefore no justification for its use as single-agent treatment. The effect of
thymostimulin on hepato-renal function requires further confirmation.
Trial Registration: Current Controlled Trials ISRCTN64487365.
Background
Hepatocellular carcinoma (HCC) currently ranks fifth
among the most common malignancies world-wide with
a rising incidence in first-world countries [1]. Although
treatment options have become more diverse in recent
years, improvements in survival rates lack far behind
those achieved in other tumor entities [2]. Benefiting
most from newer modalities are patients amenable to
local therapy, i.e. with intermediate stages of the disease,
small tumors and good liver function [3]. In contrast,
patients with large tumors, metastases or deteriorating
liver function remain without proven standard treatment
resulting in a life expectancy of less than 10% at 3 years
[5,6]. Most systemic approaches have yielded disappoint-
ing results despite major side-effects. Only sorafenib, a
new protein kinase inhibitor, has now been shown for
the first time to improve survival in patients with Child
A cirrhosis [6], leading to new recommendations on
design and patient selection in HCC trials [7].
Immunomodulation is another promising strategy
against HCC [8]. Thymostimulin - a standardized low-
molecular protein fraction containing thymosin-a1 and
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induce a selective, dose-dependent, cytotoxic immune
reaction against HCC cell lines in vitro [9,10]. Based on
the experimental data, two single-center phase II trials
using thymostimulin in patients with locally advanced
and metastasised HCC not amenable to or failing surgi-
cal and/or local therapy have been published including
one by our group [11,12]. With 63% and 79%, respec-
tively, both depicted excellent tumor control rates even
in metastatic disease and virtually no side-effects. The
two trials, however, lacked control groups. Thus, we
conducted a multi-center, randomised, placebo-con-
trolled phase III study in HCC patients according to the
same eligibility criteria at the time. Liver function (Child
classification) was used for stratification and subgroup
analysis. The aim was to evaluate if the tumor control
by thymostimulin observed in the phase II trials would
translate into improved survival as compared with best
supportive care and placebo.
Methods
Eligibility criteria
Patients with histologically proven, locally advanced or
metastatic HCC not amenable to or failing established
treatment were enrolled; locally advanced tumor was
defined as one nodule larger than 5 cm or more than 3
nodules larger than 3 cm in diameter. Pretreatment of
the HCC was allowed if tumors had progressed during
therapy. However, a treatment-free interval of at least 3
months was required prior to enrollment. Patients
between 18 and 80 years of age and a Karnofsky perfor-
mance status ≥ 60% were eligible. Exclusion criteria
were pregnancy/lactation, active second malignancy,
severe concomitant disease (e.g. cardiac failure NYHA
III-IV, serum creatinine level > 300 μmol/l) or severely
decompensated liver function (bilirubin > 5 mg/dl,
Child-Pugh > 12). None of the patients received antiviral
treatment with interferon during the study period. Ethi-
cal approval was obtained from all ethical review boards
of the participating centers before study initiation and
written informed consent from each patient before
entering the study. The study was conducted in accor-
dance with the ethical principles stated in the Declara-
tion of Helsinki and the guidelines on good clinical
practice.
Study design
The study was designed as a prospective, randomised,
controlled, double-blind, multi-centre phase III trial
comparing best supportive care plus thymostimulin with
best supportive care plus placebo (trial registration: Cur-
rent Controlled Trials ISRCTN64487365). Patients were
recruited at 12 centres in Germany (see Acknowledge-
ments); all biopsies were centrally reviewed by an
experienced pathologist (AT). Primary endpoint of the
study was 12-month survival, secondary endpoints over-
all survival, time to progression and tumor response
according to standard Response Evaluation Criteria In
Solid Tumors (RECIST criteria) [13], toxicity according
to ECOG criteria [14] and quality of life assessed by
means of the FACT-Hep questionnaire [15] (Figure 1).
A sample size of 110 patients was calculated to detect a
20% improvement in one-year-survival in a two-sided
log-rank-test with a significance level of 5% and a power
of 90%. Allowing for a drop-out rate of at least 20%, 135
patients were planned to be recruited within 24 months.
After inclusion of the last patient, a follow-up period of
12 months was scheduled.
Therapeutic procedures
Thymostimulin is a licensed immunomodulating drug
prepared from an extract of peptides from bovine thy-
mus glands (Thymophysin CytoChemia® 25/50). Follow-
ing removal of high-molecular cell components and
proteins, the low-molecular active thymus peptides are
isolated and standardized to a defined protein fraction.
Before central randomization via fax patients were stra-
tified according to liver function (Child classification)
Figure 1 Schematic presentation of the study design.
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received). They were assigned covariate-adapted to each
center to either thymostimulin 75 mg or placebo subcu-
taneously 5 days a week for one year in addition to best
supportive care. Study medication (verum and placebo)
was coded and labeled to guarantee blinding with the
first five injections performed by a medical doctor.
Further injections were administrated by the patients
themselves or home care workers and registered in a
treatment diary. Drug accountability procedures, report-
ing of (serious) adverse events and source data verifica-
tion were implemented as part of the trial monitoring
according to standard operating procedures conducted
by external monitors. Treatment with the study medica-
tion was continued for one year or until one of the fol-
lowing criteria was met: disease progression,
decompensation of liver function (bilirubin > 5 mg/dl,
INR ≥ 2.3) or performance status (Karnofsky score <
50%), unacceptable toxicity, patient refusal or
incompliance.
Pre-treatment and follow-up evaluation
Pre-treatment and follow-up evaluation included a com-
plete medical history, physical examination, blood count
and chemistry as well as performance status. Risk factors
and severity of liver disease according to Child-Pugh sta-
tus as well as prior treatment modalities were recorded at
baseline. Tumors were assessed by abdominal ultrasound,
chest X-ray and either dynamic computerized tomogra-
phy (CT) or magnetic resonance imaging (MRI). Other
imaging techniques such as radionuclide scans were
deployed as clinically indicated. Okuda, CLIP and BCLC
classifications were used for staging. Follow-up investiga-
tions without imaging were conducted every 6 weeks
including survival data as well as documentation of con-
comitant therapies and toxicity of the medication. Tumor
response using CT or MRI scanning was evaluated every
3 months according to RECIST criteria [13]: complete
response = disappearance of all demonstrable disease;
partial response = decrease ≥ 50% of the longest diameter
of the target lesion without worsening of all other dis-
ease; stable disease = no significant change in disease
[decrease < 50% or increase < 25% without new lesions];
progressive disease = increase ≥ 25% of the longest dia-
meter of the target lesion or new lesions). In addition,
quality of life assessed by means of the FACT-Hep ques-
tionnaire [15] was also measured every 3 months. Fol-
low-up was scheduled for at least one year after
enrollment, followed by three-monthly assessments in
surviving patients.
Statistical analysis
All analyses were based on the intention-to-treat (ITT)
patient population. Baseline characteristics were
expressed as median [range or 95% CI] for continuous
variables and percentages (of all patients randomised)
for categorical variables. Survival time and time to pro-
gression were calculated from the time of randomisation
to the date of death or date of progression, respectively.
Univariate survival curves for baseline predictors were
established with the Kaplan-Meier method and quantita-
tively expressed as median survival time [95% CI]. As
predefined in the study protocol, a stepwise backward
Cox’s regression analysis of survival was used to adjust
the treatment effect according to relative risks imposed
by baseline predictors. The following variables were cho-
sen for the first model: age, gender and Karnofsky per-
formance status; the presence of liver cirrhosis and
Child classification; Okuda, CLIP and BCLC classifica-
tion; AFP level, multifocal tumor manifestation, ascites,
vascular invasion and extrahepatic metastases; treatment
with thymostimulin or placebo and treatment with other
therapeutic modalities before study entry. The frequency
of adverse events was compared between groups using
Chi-square tests. All calculations were done with the
SPSS package (version 15.0).
Results
Patients
A total of 135 patients were enrolled between October
2002 and March 2005, and randomly assigned to treat-
ment with thymostimulin (n = 67) or placebo (n = 68).
Detailed demographic data and tumor-related character-
istics are depicted in Table 1. Most patients had liver
cirrhosis, and the majority of tumors was staged as
advanced HCC (Okuda stage II; CLIP 2-3 points; BCLC
stage C) with multinodular tumor growth, vascular inva-
sion and extrahepatic spread. Less than a third of
patients had been treated prior to enrollment with surgi-
cal resection (R1 or R2 resection), percutaneous ethanol
injection (PEI; range 1-5 sessions), transarterial che-
moembolisation (TACE; range 1-7 sessions) or systemic
hormone- and/or chemotherapy (somatostatin in 7/14
cases; single or combination therapy with tamoxifen,
d o x o r u b i c i no rp l a t i nd e r i v ates), but suffered from
tumor progression. All baseline characteristics were well
balanced between the two groups.
Following randomisation, 6 patients in the thymostimu-
lin group and one patient in the placebo group did not
receive the allocated treatment (Figure 2). Their data were
included in the intention-to-treat analysis; a subgroup ana-
lysis excluding these patients did not reveal a different out-
come (data not shown). The remaining patients received
treatment as scheduled, in most cases until disease pro-
gression or deterioration of liver function or performance
status. One patient in each group received salvage therapy
after tumor progression, in the placebo group TACE, in
the thymostimulin group tamoxifen. Secondary tumors
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each group; in the thymostimulin group, treatment of the
patient had to be stopped early due to a hypopharyngeal
cancer, in the placebo group the secondary urothelial can-
cer was detected after 12 months of treatment of the
patient. Only 12 patients (thymostimulin, n = 7 [10%]; pla-
cebo, n = 5 [7%]) received the study medication for a
whole year. At the time of analysis, all patients had
stopped their allocated treatment. The median follow-up
was 5.2 months [95% CI 4.0-7.3] in the thymostimulin
group and 5.6 months [95% CI 3.6-7.3] in the placebo
group, the median length of treatment 3.3 months [range
0 to 12 months] for both groups.
Survival and tumor response
For the thymostimulin group, the univariate probability of
survival at 6 and 12 months was 42% [95% CI 29-55] and
28% [95% CI 17-41], respectively, with a median survival
time of 5.0 months [95% CI 3.7-6.3]. There was no signifi-
cant difference in univariate survival compared with the
placebo group with a 6- and 12-month survival of 40%
[95% CI 27-54] and 32% [95% CI 19-44], respectively, and
a median survival time of 5.2 months [95% CI 3.5-6.9; p =
0.87; HR = 1.04 [95% CI 0.7-1.6]]. The Kaplan-Meier
curve for overall survival is shown in Figure 3A.
The analysis of the objective tumor response showed
no complete response in any of the patients. 22 [33%]
Table 1 Baseline characteristics of patients
Baseline characteristics Placebo n = 68 Thymostimulin n = 67
Patients
Male/female (%) 82/18 84/16
Median age (years (range)) 63 (39-76) 63 (48-79)
Median body weight (kg (range)) 80 (39-108) 79 (58-112)
Mean Karnofsky score (% (range)) 87 (60-100) 89 (60-100)
Cause of liver disease (%)
Alcohol abuse 47 55
HBV/HCV 21 18
Other 32 27
Stage of liver disease (%)
Liver cirrhosis 90 85
Child classification: A or no cirrhosis/B/C 63/28/9 65/32/3
Tumor stage (%)
Okuda stage I/II/III 32/56/12 35/54/11
CLIP score 0/1/2/3/4-6 0/18/35/25/22 0/15/29/29/27
BCLC stage A/B/C/D 0/16/69/15 0/22/66/12
a-FP (%)
< 400 ng/ml 57 57
> 400 ng/ml 43 43
Tumor characteristics (%)
Ascites 46 37
Portal vein thrombosis 32 42
Multifocal tumor manifestation 88 91
Extrahepatic metastases 40 45
Hepato-renal laboratory parameters
Mean urea (mg/dl [95% CI]) 4.3 [2.8-5.8] 3.7 [2.8-4.5]
Mean creatinine (mg/dl [95% CI]) 0.4 [0.3-0.6] 0.5 [0.4-0.6]
Mean sodium (mmol/l [95% CI]) 137 [136-138] 137 [136-138]





Percutaneous ethanol injection (PEI) 4 2
Transarterial chemoembolisation (TACE) 25 20
Systemic hormone- and/or chemotherapy 12 9
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randomised (- survival function, + censored): A) all patients; B) subgroup analysis Child A patients; C) subgroup analysis BCLC B patients; D)
subgroup analysis BCLC C patients.
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stable disease or a partial response (disease-control rate)
in the first 6 months followed by progressive disease
thereafter. There was, however, a similar tumor response
rate in the placebo group in 20 [29%] out of 68 patients,
a n dt i m et op r o g r e s s i o nd i dn ot statistically differ
between groups [p = 0.60, HR = 1.13 [95% CI 0.7-1.8]]
with a median of 5.3 months [95% CI 2.0-8.6; thymosti-
mulin] and 2.9 months [95% CI 2.6-3.1; placebo],
respectively (Figure 4A).
As predefined in the study protocol, an exploratory
Cox’s regression analysis of survival and time to pro-
gression was used to adjust the treatment effect of thy-
mostimulin or placebo according to the relative risks
imposed by baseline characteristics. Thus, adjustment
for age, gender, Karnofsky performance status, presence
of liver cirrhosis and stage of liver disease (Child classifi-
cation), tumor stage (Okuda, CLIP and BCLC classifica-
tion), invasive tumor phenotype (vascular invasion or
metastases) or treatment prior to enrollment did not
reveal a therapeutic effect of thymostimulin in any sub-
group of patients. Kaplan-Meier curves for overall survi-
val and time to progression in patients with Child A
cirrhosis or tumor stage BCLC B and C are shown in
Figure 3B-D and Figure 4B-D, respectively.
Safety
Compliance with the allocated treatment was high with
an average of 94% and 92% of patients receiving all 5
injections a week in every 6 week-cycle in the thymosti-
mulin and placebo group, respectively (n.s.). While skin
reactions following injection are the only known side-
effects of thymostimulin [11,12], it has been shown to
reduce chemotherapy-induced toxicity, in particular mye-
losuppression and infectious episodes [16]. In our study,
219 adverse events were reported - 95 in the placebo and
124 in the thymostimulin group (n.s.). Skin reactions
caused the early withdrawal from the trial of two patients
on thymostimulin and one patient on placebo (n.s., Table
2). One more patient on placebo withdrew due to adverse
events, i.e. diarrhea after injection (Figure 2). 139/219
adverse events were classified as serious - 85 in the pla-
cebo and 54 in the thymostimulin group. Using Chi-
square-tests, we found a lower incidence of renal failure,
ascites and dyspnoea in patients treated with thymosti-
mulin (Table 2). In contrast, hematological or infectious
complications were equally common in both groups.
Quality of life
Quality of life was assessed by means of the FACT-Hep
questionnaire at baseline and every 6 weeks thereafter.
There was no difference between groups in any of the
questionnaire’s subdomains at any time point.
Discussion
This is the first randomised controlled trial analysing
the effect of thymostimulin or similar thymic extracts
containing thymosin-a1 on HCC growth and survival of
patients. We found no difference in either 12-month/
overall survival or time to progression between the
treatment and placebo group when using the compound
as a single-agent regimen. Despite its good safety profile,
thymostimulin failed to prevent the occurrence of infec-
tious complications as previously reported, although the
incidence of renal decompensation and ascites was
reduced as compared with placebo.
There has been a renewed interest in compounds con-
taining thymosin-a1 over the past years for their poten-
tial immune-stimulating and anti-tumorous properties
resulting in ongoing large phase II/III trials in mela-
noma or hepatitis C patients [17-19]. The underlying
mechanism of action of these compounds is thought to
be an increase of proinflammatory cytokines, T cell pro-
liferation and differentiation as well as antigen expres-
sion on tumor cells resulting in the induction of a
tumor-specific cytotoxicity [19,20]. Indeed, preliminary
phase II trials of thymostimulin in patients with HCC
were notable for their tumor response rate and the
occurrence of complete responses, resulting in a median
overall survival of up to 11.5 months [11,12]. This
observation could not be repeated in the current phase
III trial. Rather, thymostimulin had no beneficial effect
on tumor progression as compared with placebo, and
thus did not improve survival.
Although superior in design than the phase II trials,
there are several limitations to our study originating in
the concept from 2002. Based on the previous experi-
ences, patients now generally classified as at the inter-
mediate, advanced and terminal stage of their disease
(BCLC classification) were enrolled resulting in a median
survival of only 5 months and early withdrawal due to
decompensation of liver function or performance status
in more than a third of patients. In his recent recommen-
dations, Llovet et al. clearly discouraged study designs
including patients at different stages of the disease, in
particular regarding liver function [7]. Survival in Child B
and C cirrhosis may be too short to capture any benefit
from the trial medication. As intended in our study pro-
tocol, we stratified patients prior to randomisation
according to liver function (Child classification) and pre-
vious treatment for HCC (received or not received).
Results in the final analysis were additionally adjusted for
baseline characteristics including liver function, tumor
stage and tumor phenotype such as vascular invasion or
metastases. We found no effect of thymostimulin in any
of the subgroups, but overall survival was better in Child
A patients, although not as good as in the SHARP trial
Dollinger et al. BMC Cancer 2010, 10:457
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Page 7 of 11Figure 4 Estimate of time to progression. Kaplan-Meier graph showing time to progression in percentage of patients randomised (- survival
function, + censored): A) all patients; B) subgroup analysis Child A patients; C) subgroup analysis BCLC B patients; D) subgroup analysis BCLC C
patients.
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limitation in design has to be acknowledged for the inter-
pretation of our results, and should be obsolete in future
trials.
In view of the advanced stage of disease of many of
the patients, intervals between assessments of tumor
response by CT or MRI scanning every three months
may have been chosen too long, too. Differences in
tumor progression between the two groups within the
first 3 months, in particular, might have not registered
confounding the secondary endpoint time to progres-
sion. Finally, a majority of patients featured alcoholic
cirrhosis as underlying liver disease, only a minority
viral hepatitis. Although uncommon for many other
regions in the world and therefore potentially limiting
comparability, the distribution reflects the origin of the
patients in Northern Europe and matches official obser-
vations of the German Federal Statistical Office [21].
Despite the limitations of the study design, however, we
found no convincing evidence for a therapeutic effect of
thymostimulin used as a single agent, in particular with
regards to the most stringent study endpoint overall
survival. A potential impact as “biological response
modifier” [17] as part of a combination therapy, recently
suggested in two promising phase II trials using thymo-
sin-a1 containing compounds in combination with
TACE for advanced HCC [22,23], will have to be con-
firmed in a controlled trial.
In addition to their anti-tumorous potential, thymo-
sin-a1 containing compounds have also been associated
with improved immune function and a reduction of
infectious complications [24]. Only skin reactions fol-
lowing injection are known side-effects [18,19], while
several studies demonstrated their ability to prevent
myelosuppression and infections during chemotherapy
[16,25]. In our study, most adverse events could be
related to the progressive tumor and subsequently dete-
riorating liver function of the patients. In this cohort,
thymostimulin failed to reduce infections, bearing in
mind that neutropenia did not occur as a complication
of the disease. Interesting, but remaining a mere obser-
vation in a study not designed to study this endpoint, is
the lower incidence of renal failure and ascites in
patients treated with thymostimulin as compared with
Table 2 Comparison between groups of (serious) adverse events (AE) graded according to ECOG criteria and occurring
in more than 2% of all patients (n = 135; significance level p < 0.05)
ECOG toxicity criteria Placebo (n = 68) Thymostimulin (n = 67) p-value
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4 single tests
Haematology
Anaemia 1 1 2 0.9880
Constitutional symptoms
Fatigue 2 2 1 1 1 0.2525
Dermatology
Injection site reaction 1 1 3 0.1663
Pain
Abdominal pain 1 2 1 2 0.9852
Arthralgia 1 3 0.3029
Infection
Infection without neutropenia 3 4 1133 0.8077
Gastrointestinal/Hepatic
Diarrhoea 1 2 2 2 0.6831
Hyperbilirubinaemia 2 1 0.5681
Elevated transaminases 1 2 1212 0.7128
GI haemorrhage 4 2 4 6 0.2728
Ascites (without renal failure) 1 14 3 2 6 0.0323
Renal
Elevated creatinine or urea 5 2 1 1 0.0887
Renal failure (with ascites) 7 5 2 0.0052
Pulmonary
Dyspnoea 3 4 1 0.0303
Pleural effusion 6 1 0.0548
Neurology
Encephalopathy 6 5 0.7726
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thymosin fraction 5 (TF5) in an animal model of experi-
mentally induced uremia [26].
Conclusions
In conclusion, our placebo-controlled, double-blind and
randomised study found no evidence of a survival bene-
fit or lasting tumor response in patients with locally
advanced or metastasised HCC treated with thymosti-
mulin. Thus, it cannot be recommended as single-agent
treatment. This does not preclude testing thymostimulin
or similar compounds as part of a combination therapy,
although better understanding of their potential mode
of action is certainly needed in doing so.
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